

# **Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy**

Jun 04, 2021

---

**Source URL:** <https://prod1.novartis.com/us-en/news/media-releases/novartis-investigational-checkpoint-inhibitor-tislelizumab-met-primary-endpoint-overall-survival-pivotal-phase-iii-trial-esophageal-cancer-after-systemic-therapy-0>

## **List of links present in page**

1. <https://prod1.novartis.com/us-en/us-en/news/media-releases/novartis-investigational-checkpoint-inhibitor-tislelizumab-met-primary-endpoint-overall-survival-pivotal-phase-iii-trial-esophageal-cancer-after-systemic-therapy-0>